Sarah Cannon Research Institute Adds Physician Researcher
Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator.
NASHVILLE, Tenn., May 11, 2005 -- Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator. A clinical researcher with The Sarah Cannon Cancer Center since 1993, Meluch is also a member of Tennessee Oncology, P.L.L.C.
Dr. Meluch joins SCRI's primary investigator team, directed by F. Anthony Greco, M.D., which also includes John D. Hainsworth, M.D., Howard A. Burris III, M.D., Denise A. Yardley, M.D., David Spigel, M.D. and Suzanne F. Jones, PharmD.
"Dr. Meluch is a thought leader who brings excellent qualifications and experience to our team," said Dr. Greco. "His research interests and passion for advancing patient care will enable us to expand our menu of clinical trials."
Meluch received his undergraduate training at St. Louis University in Missouri, and his medical doctorate from The Ohio State University College of Medicine. He completed an internal medicine residency program and then a fellowship in both hematology and oncology at the University of Alabama in Birmingham; he is board certified in all three subspecialties. His research interests and publications are in malignancies of the upper aerodigestive system, esophagus, head, neck and genitourinary tract.
"Dr. Meluch's vast knowledge and experience as a practicing physician and researcher made him the perfect candidate for this role," said Mark Cianciolo, CEO of Sarah Cannon Research Institute. "His appointment is in line with our goals to expand our team of physician researchers to enhance our ability to develop more clinical trials for more patients."
"I am honored and excited by the opportunity to further my research interests and expand the scope of SCRI's investigations to improve outcomes for people fighting cancer," said Dr. Meluch.
Sarah Cannon Research Institute, a new company created by HCA's MidAmerica Division and Tennessee Oncology, is dedicated to creating and advancing solutions for a healthier tomorrow through clinical research. The institute is the largest community-based research program in the United States, currently conducting clinical trials through a network of more than 600 oncologists in 25 states.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
